Magnetar Financial LLC Has $419,000 Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Magnetar Financial LLC lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 82.7% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,476 shares of the specialty pharmaceutical company’s stock after selling 16,655 shares during the quarter. Magnetar Financial LLC’s holdings in Jazz Pharmaceuticals were worth $419,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Rise Advisors LLC increased its position in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 203 shares during the period. Cape Investment Advisory Inc. raised its position in shares of Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares in the last quarter. Assetmark Inc. grew its position in Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 119 shares in the last quarter. Newbridge Financial Services Group Inc. raised its holdings in Jazz Pharmaceuticals by 254.5% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 336 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Jazz Pharmaceuticals by 107.4% during the 1st quarter. Covestor Ltd now owns 618 shares of the specialty pharmaceutical company’s stock worth $74,000 after purchasing an additional 320 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded up $1.03 during trading on Monday, reaching $112.60. The company’s stock had a trading volume of 49,928 shares, compared to its average volume of 669,948. The firm has a market cap of $7.10 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 1.72 and a beta of 0.58. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $146.70. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The firm has a 50 day moving average of $107.22 and a 200-day moving average of $114.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The firm had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. Research analysts expect that Jazz Pharmaceuticals plc will post 15.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JAZZ. UBS Group decreased their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. StockNews.com cut shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 5th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price on the stock. Barclays dropped their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Finally, Needham & Company LLC reduced their price objective on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, June 20th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $185.86.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.